<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617497</url>
  </required_header>
  <id_info>
    <org_study_id>S61745</org_study_id>
    <nct_id>NCT03617497</nct_id>
  </id_info>
  <brief_title>Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease</brief_title>
  <acronym>PESAD</acronym>
  <official_title>Prevalence of Epilepsy and Sleep Wake Disorders in Alzheimer Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer disease is the most common of the neurodegenerative diseases. Epilepsy and sleep
      wake disorders are co-morbid conditions of Alzheimer disease. The investigators propose a
      prospective study using long-term EEG monitoring in combination with polysomnography to
      determine prevalence of epilepsy and sleep wake disorders in Alzheimer disease, and correlate
      these findings with clinical data, Alzheimer disease biomarkers and imaging studies (MRI and
      amyloid/tau-PET). In selected patients, the investigators will perform EEG studies with
      foramen ovale electrodes. The ultimate goal is to improve the outcome of patients with
      Alzheimer disease by early treatment of epilepsy and restoring sleep-wake disturbances.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer disease is the most common of the neurodegenerative diseases. Epilepsy and sleep
      wake disorders are co-morbid conditions of Alzheimer disease, and there is evidence to
      suggest that the interactions are bidirectional. Neuronal activity promotes the production
      and secretion of amyloid β, which could actually drive pathogenesis early in the course of
      Alzheimer disease, and has been described in sleep wake disorders and epilepsy. Epileptic
      seizures in Alzheimer disease are often subtle, nocturnal and easily overlooked. We propose a
      prospective study using long-term EEG monitoring in combination with polysomnography to
      diagnose epilepsy and sleep wake disorders in Alzheimer disease, and correlate these findings
      with clinical data, Alzheimer disease biomarkers and imaging studies (MRI and
      amyloid/tau-PET). It is the hypothesis of the investigators that participants with Alzheimer
      disease and interictal spikes or specified sleep wake disorders (e.g., frequent nocturnal
      awakenings) during 48 hour scalp EEG and polysomnography are at risk for having hippocampal
      seizures, which are often clinically silent and not detected on scalp EEG. The investigators
      will invite 15 of these participants to undergo EEG studies with foramen ovale electrodes to
      determine the prevalence of these hippocampal seizures. The ultimate goal is to improve the
      outcome of patients with Alzheimer disease by early treatment of epilepsy and restoring
      sleep-wake disturbances.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>The investigators will perform 48-hour ambulatory scalp-EEG and polysomnography in 100 participants with Alzheimer disease and 30 age-and gender-matched healthy participants. The investigators will determine the prevalence of 1.) epileptic discharges and epileptic seizures, 2.) sleep wake disorders and 3.) the interaction of epilepsy and sleep wake disorders in these two groups. A subgroup of 15 of these 100 participants with Alzheimer disease, with interictal epileptic spikes or sleep wake disorders (e.g., frequent nocturnal awakenings) will be invited to undergo an invasive EEG study with foramen ovale electrodes to determine the prevalence of hippocampal seizures, which are usually clinically silent and not detected with scalp EEG.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epilepsy</measure>
    <time_frame>during EEG recording</time_frame>
    <description>presence of epileptic activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep wake disorder</measure>
    <time_frame>during polysomnographic recording</time_frame>
    <description>presence of sleep wake disorders</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Alzheimer Dementia</condition>
  <condition>Epilepsy</condition>
  <condition>Sleep Wake Disorders</condition>
  <arm_group>
    <arm_group_label>Healthy control participants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Age- and gender matched healthy participant (n=30) with no cognitive problems and normal amyloid PET scan will undergo 48 hour scalp EEG and polysomnography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with Alzheimer disease (n=100) will undergo 48 hour scalp EEG and polysomnography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer disease with high seizure risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selected participants with Alzheimer disease, with higher risk for silent hippocampal seizures after 48 hour scalp EEG and polysomnography (e.g. presence of interictal spikes or frequent nocturnal awakenings) (n=15) will undergo scalp EEG with foramen ovale electrodes with polysomnography</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>scalp EEG and polysomnography</intervention_name>
    <description>48 hour 22 channel EEG with polysomnography</description>
    <arm_group_label>Alzheimer disease</arm_group_label>
    <arm_group_label>Alzheimer disease with high seizure risk</arm_group_label>
    <arm_group_label>Healthy control participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>scalp EEG with foramen ovale electrodes with polysomnography</intervention_name>
    <description>long-term scalp EEG with additional foramen ovale electrodes with polysomnography</description>
    <arm_group_label>Alzheimer disease with high seizure risk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant must be able to understand the nature of the study and has the opportunity
             to have any questions answered. The participant has voluntarily signed the independent
             Review Board (IRB)/independent Ethics Committee (IEC) approved Informed Consent, prior
             to the conduct of any study procedures. If the participant is not fully competent,
             full informed consent must be obtained from a representative and assent must be
             obtained from the participant.

          2. Participant who meets the National Institute on Aging and the Alzheimer's Association
             (NIA-AA) clinical criteria for mild cognitive impairment or probable Alzheimer
             Disease, and have:

               -  Clinical Dementia Rating (CDR)-Global Score of 0.5

               -  A Mini-Mental State Examination (MMSE) score of 22 to 30

               -  Repeatable Battery for the Assessment of Neuropsychological Status-Delayed Memory
                  Index (RBANS-DMI) score of 85 or lower

          3. Participant has a positive amyloid Positron Emission Tomography (PET) scan.

          4. Participant has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4.

          5. Participant has an identified, reliable, study partner (e.g., family member), who has
             frequent contact with the participant and who will provide information as to the
             participant's cognitive and functional abilities.

        Exclusion Criteria:

          1. Participant has evidence of any other clinically significant neurological disorder
             other than Alzheimer disease, including but not limited to:

               -  Parkinson's disease

               -  vascular dementia

               -  significant cerebrovascular abnormalities

               -  frontal-temporal dementia

               -  Huntington's disease

               -  normal pressure hydrocephalus

               -  brain tumor

               -  progressive supranuclear palsy

               -  seizure disorder

               -  subdural hematoma

               -  multiple sclerosis

               -  history of significant head trauma followed by persistent neurologic deficits

               -  known structural brain abnormalities

               -  obstructive sleep apnea syndrome treated with continuous positive airway pressure
                  (CPAP)

          2. Participant has a screening MRI scan, interpreted by a radiologist with evidence of
             infection, infarction (including multiple lacunas in a critical memory structure), or
             other focal lesions.

          3. Participant has a history of or currently has schizophrenia, schizoaffective disorder
             or bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders
             (DSM)-V or International Classification of Diseases (ICD)-10 criteria.

          4. Participant has a current diagnosis or history of drug or alcohol abuse (by DSM-V
             criteria) within 24 months prior to the study.

          5. Participant has a history or evidence of a malignancy within the 2 years prior to the
             study.

          6. Participant has a known history of Human Immunodeficiency Virus (HIV) infection.

          7. Participant has had surgery under general anesthesia within 3 months prior to the
             study.

          8. Receipt of an investigational product within a time period equal to 5 half-lives, if
             known, or within 6 weeks (for small molecules) or 6 months (for monoclonal antibodies
             or other biologics) prior the study.

          9. Participant has any history of prior receipt of active immunotherapy directed against
             tau or amyloid.

         10. Participant is taking anti-epileptic drugs or benzodiazepines.

         11. Participant has an abnormally low vitamin B 12 (cobalamin), abnormal thyroxine (T4) or
             an abnormally high thyroid stimulating hormone (TSH) that is considered clinically
             significant by the investigator.

         12. Subject has any visual, auditory or other impairment that in the Investigator's
             opinion would preclude collection of outcome measures.

         13. In the opinion of the investigator, the subject has any clinically significant or
             uncontrolled medical or psychiatric illness, or has had an infection requiring medical
             intervention in the past 30 days.

         14. Subject has had a myocardial infarction, unstable angina, stroke, transient ischemic
             attack or required intervention for any of these conditions (e.g., coronary artery
             bypass graft, percutaneous coronary intervention via cardiac catheterization,
             thrombolytic therapy), within 6 months of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Van Paesschen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ and KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wim Van Paesschen, MD PhD</last_name>
    <phone>+3216344332</phone>
    <email>wim.vanpaesschen@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bertien Buyse, MD PhD</last_name>
    <phone>+3216341426</phone>
    <email>bertien.buyse@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven, department of Neurology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://www.missionlucidity.com/</url>
    <description>Mission Lucidity: Decoding Dementia</description>
  </link>
  <reference>
    <citation>Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev Neurol. 2014 Feb;10(2):115-9. doi: 10.1038/nrneurol.2013.269. Epub 2013 Dec 24. Review.</citation>
    <PMID>24366271</PMID>
  </reference>
  <reference>
    <citation>Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2016 Nov 25;354(6315):1004-1008. Review.</citation>
    <PMID>27885006</PMID>
  </reference>
  <reference>
    <citation>Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014 Aug;71(8):971-7. doi: 10.1001/jamaneurol.2014.1173.</citation>
    <PMID>24887018</PMID>
  </reference>
  <reference>
    <citation>Noebels J. A perfect storm: Converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia. 2011 Jan;52 Suppl 1:39-46. doi: 10.1111/j.1528-1167.2010.02909.x.</citation>
    <PMID>21214538</PMID>
  </reference>
  <reference>
    <citation>Horváth A, Szűcs A, Barcs G, Noebels JL, Kamondi A. Epileptic Seizures in Alzheimer Disease: A Review. Alzheimer Dis Assoc Disord. 2016 Apr-Jun;30(2):186-92. doi: 10.1097/WAD.0000000000000134. Review.</citation>
    <PMID>26756385</PMID>
  </reference>
  <reference>
    <citation>Lam AD, Deck G, Goldman A, Eskandar EN, Noebels J, Cole AJ. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease. Nat Med. 2017 Jun;23(6):678-680. doi: 10.1038/nm.4330. Epub 2017 May 1.</citation>
    <PMID>28459436</PMID>
  </reference>
  <reference>
    <citation>Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013 Sep 1;70(9):1158-66. doi: 10.1001/jamaneurol.2013.136.</citation>
    <PMID>23835471</PMID>
  </reference>
  <reference>
    <citation>Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Honma SM, Dowling AF, Darwish SM, Van Berlo V, Barnes DE, Mantle M, Karydas AM, Coppola G, Roberson ED, Miller BL, Garcia PA, Kirsch HE, Mucke L, Nagarajan SS. Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. Ann Neurol. 2016 Dec;80(6):858-870. doi: 10.1002/ana.24794. Epub 2016 Nov 7.</citation>
    <PMID>27696483</PMID>
  </reference>
  <reference>
    <citation>Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL. Epileptic activity in Alzheimer's disease: causes and clinical relevance. Lancet Neurol. 2017 Apr;16(4):311-322. doi: 10.1016/S1474-4422(17)30044-3. Review.</citation>
    <PMID>28327340</PMID>
  </reference>
  <reference>
    <citation>Lam AD, Zepeda R, Cole AJ, Cash SS. Widespread changes in network activity allow non-invasive detection of mesial temporal lobe seizures. Brain. 2016 Oct;139(Pt 10):2679-2693. Epub 2016 Jul 29.</citation>
    <PMID>27474219</PMID>
  </reference>
  <reference>
    <citation>Rabinowicz AL, Starkstein SE, Leiguarda RC, Coleman AE. Transient epileptic amnesia in dementia: a treatable unrecognized cause of episodic amnestic wandering. Alzheimer Dis Assoc Disord. 2000 Oct-Dec;14(4):231-3.</citation>
    <PMID>11186602</PMID>
  </reference>
  <reference>
    <citation>Zarea A, Charbonnier C, Rovelet-Lecrux A, Nicolas G, Rousseau S, Borden A, Pariente J, Le Ber I, Pasquier F, Formaglio M, Martinaud O, Rollin-Sillaire A, Sarazin M, Croisile B, Boutoleau-Bretonnière C, Ceccaldi M, Gabelle A, Chamard L, Blanc F, Sellal F, Paquet C, Campion D, Hannequin D, Wallon D; PHRC GMAJ Collaborators. Seizures in dominantly inherited Alzheimer disease. Neurology. 2016 Aug 30;87(9):912-9. doi: 10.1212/WNL.0000000000003048. Epub 2016 Jul 27.</citation>
    <PMID>27466472</PMID>
  </reference>
  <reference>
    <citation>Tai XY, Koepp M, Duncan JS, Fox N, Thompson P, Baxendale S, Liu JY, Reeves C, Michalak Z, Thom M. Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections. Brain. 2016 Sep;139(Pt 9):2441-55. doi: 10.1093/brain/aww187. Epub 2016 Aug 7.</citation>
    <PMID>27497924</PMID>
  </reference>
  <reference>
    <citation>Horváth A, Szűcs A, Barcs G, Kamondi A. Sleep EEG Detects Epileptiform Activity in Alzheimer's Disease with High Sensitivity. J Alzheimers Dis. 2017;56(3):1175-1183. doi: 10.3233/JAD-160994.</citation>
    <PMID>28128769</PMID>
  </reference>
  <reference>
    <citation>Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012 May 10;74(3):467-74. doi: 10.1016/j.neuron.2012.03.023.</citation>
    <PMID>22578498</PMID>
  </reference>
  <reference>
    <citation>McCurry SM, Logsdon RG, Teri L, Gibbons LE, Kukull WA, Bowen JD, McCormick WC, Larson EB. Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. J Geriatr Psychiatry Neurol. 1999 Summer;12(2):53-9.</citation>
    <PMID>10483925</PMID>
  </reference>
  <reference>
    <citation>Ownby RL, Peruyera G, Acevedo A, Loewenstein D, Sevush S. Subtypes of sleep problems in patients with Alzheimer disease. Am J Geriatr Psychiatry. 2014 Feb;22(2):148-56. doi: 10.1016/j.jagp.2012.08.001. Epub 2013 Jan 11.</citation>
    <PMID>23567445</PMID>
  </reference>
  <reference>
    <citation>Ju YE, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley SP, Morris JC, Holtzman DM. Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013 May;70(5):587-93. doi: 10.1001/jamaneurol.2013.2334.</citation>
    <PMID>23479184</PMID>
  </reference>
  <reference>
    <citation>Pavlova M. Circadian Rhythm Sleep-Wake Disorders. Continuum (Minneap Minn). 2017 Aug;23(4, Sleep Neurology):1051-1063. doi: 10.1212/CON.0000000000000499. Review.</citation>
    <PMID>28777176</PMID>
  </reference>
  <reference>
    <citation>Saeed Y, Abbott SM. Circadian Disruption Associated with Alzheimer's Disease. Curr Neurol Neurosci Rep. 2017 Apr;17(4):29. doi: 10.1007/s11910-017-0745-y. Review.</citation>
    <PMID>28324298</PMID>
  </reference>
  <reference>
    <citation>Foldvary-Schaefer NR, Waters TE. Sleep-Disordered Breathing. Continuum (Minneap Minn). 2017 Aug;23(4, Sleep Neurology):1093-1116. doi: 10.1212/01.CON.0000522245.13784.f6. Review.</citation>
    <PMID>28777178</PMID>
  </reference>
  <reference>
    <citation>Lim AS, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep Fragmentation and the Risk of Incident Alzheimer's Disease and Cognitive Decline in Older Persons. Sleep. 2013 Jul 1;36(7):1027-1032.</citation>
    <PMID>23814339</PMID>
  </reference>
  <reference>
    <citation>Lim MM, Gerstner JR, Holtzman DM. The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegener Dis Manag. 2014;4(5):351-62. doi: 10.2217/nmt.14.33. Review.</citation>
    <PMID>25405649</PMID>
  </reference>
  <reference>
    <citation>Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009 Nov 13;326(5955):1005-7. doi: 10.1126/science.1180962. Epub 2009 Sep 24.</citation>
    <PMID>19779148</PMID>
  </reference>
  <reference>
    <citation>Slats D, Claassen JA, Lammers GJ, Melis RJ, Verbeek MM, Overeem S. Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls. Curr Alzheimer Res. 2012 Dec;9(10):1119-25.</citation>
    <PMID>22742854</PMID>
  </reference>
  <reference>
    <citation>Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, Bateman RJ, Holtzman DM. Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med. 2012 Sep 5;4(150):150ra122. doi: 10.1126/scitranslmed.3004291.</citation>
    <PMID>22956200</PMID>
  </reference>
  <reference>
    <citation>Pase MP, Himali JJ, Grima NA, Beiser AS, Satizabal CL, Aparicio HJ, Thomas RJ, Gottlieb DJ, Auerbach SH, Seshadri S. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017 Sep 19;89(12):1244-1250. doi: 10.1212/WNL.0000000000004373. Epub 2017 Aug 23.</citation>
    <PMID>28835407</PMID>
  </reference>
  <reference>
    <citation>Lim AS, Yu L, Kowgier M, Schneider JA, Buchman AS, Bennett DA. Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol. 2013 Dec;70(12):1544-51. doi: 10.1001/jamaneurol.2013.4215.</citation>
    <PMID>24145819</PMID>
  </reference>
  <reference>
    <citation>Reynolds CF 3rd, Kupfer DJ, Taska LS, Hoch CC, Sewitch DE, Restifo K, Spiker DG, Zimmer B, Marin RS, Nelson J, et al. Sleep apnea in Alzheimer's dementia: correlation with mental deterioration. J Clin Psychiatry. 1985 Jul;46(7):257-61.</citation>
    <PMID>4008448</PMID>
  </reference>
  <reference>
    <citation>Ancoli-Israel S, Klauber MR, Butters N, Parker L, Kripke DF. Dementia in institutionalized elderly: relation to sleep apnea. J Am Geriatr Soc. 1991 Mar;39(3):258-63.</citation>
    <PMID>2005339</PMID>
  </reference>
  <reference>
    <citation>Daulatzai MA. Evidence of neurodegeneration in obstructive sleep apnea: Relationship between obstructive sleep apnea and cognitive dysfunction in the elderly. J Neurosci Res. 2015 Dec;93(12):1778-94. doi: 10.1002/jnr.23634. Epub 2015 Aug 24. Review.</citation>
    <PMID>26301370</PMID>
  </reference>
  <reference>
    <citation>Troussière AC, Charley CM, Salleron J, Richard F, Delbeuck X, Derambure P, Pasquier F, Bombois S. Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1405-8. doi: 10.1136/jnnp-2013-307544. Epub 2014 May 14.</citation>
    <PMID>24828897</PMID>
  </reference>
  <reference>
    <citation>Pornsriniyom D, Kim Hw, Bena J, Andrews ND, Moul D, Foldvary-Schaefer N. Effect of positive airway pressure therapy on seizure control in patients with epilepsy and obstructive sleep apnea. Epilepsy Behav. 2014 Aug;37:270-5. doi: 10.1016/j.yebeh.2014.07.005. Epub 2014 Aug 12.</citation>
    <PMID>25117208</PMID>
  </reference>
  <reference>
    <citation>Sheth SA, Aronson JP, Shafi MM, Phillips HW, Velez-Ruiz N, Walcott BP, Kwon CS, Mian MK, Dykstra AR, Cole A, Eskandar EN. Utility of foramen ovale electrodes in mesial temporal lobe epilepsy. Epilepsia. 2014 May;55(5):713-24. doi: 10.1111/epi.12571. Epub 2014 Mar 7.</citation>
    <PMID>24605889</PMID>
  </reference>
  <reference>
    <citation>Risse SC, Lampe TH, Bird TD, Nochlin D, Sumi SM, Keenan T, Cubberley L, Peskind E, Raskind MA. Myoclonus, seizures, and paratonia in Alzheimer disease. Alzheimer Dis Assoc Disord. 1990 Winter;4(4):217-25.</citation>
    <PMID>2264979</PMID>
  </reference>
  <reference>
    <citation>Ju YS, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, Fagan AM, Mignot E, Zempel JM, Claassen JAHR, Holtzman DM. Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain. 2017 Aug 1;140(8):2104-2111. doi: 10.1093/brain/awx148.</citation>
    <PMID>28899014</PMID>
  </reference>
  <reference>
    <citation>Subota A, Pham T, Jetté N, Sauro K, Lorenzetti D, Holroyd-Leduc J. The association between dementia and epilepsy: A systematic review and meta-analysis. Epilepsia. 2017 Jun;58(6):962-972. doi: 10.1111/epi.13744. Epub 2017 Apr 11. Review.</citation>
    <PMID>28397967</PMID>
  </reference>
  <reference>
    <citation>Malow A, Bowes RJ, Ross D. Relationship of temporal lobe seizures to sleep and arousal: a combined scalp-intracranial electrode study. Sleep. 2000 Mar 15;23(2):231-4.</citation>
    <PMID>10737340</PMID>
  </reference>
  <reference>
    <citation>Liedorp M, Stam CJ, van der Flier WM, Pijnenburg YA, Scheltens P. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cogn Disord. 2010;29(5):432-7. doi: 10.1159/000278620. Epub 2010 May 26.</citation>
    <PMID>20502017</PMID>
  </reference>
  <reference>
    <citation>McBride AE, Shih TT, Hirsch LJ. Video-EEG monitoring in the elderly: a review of 94 patients. Epilepsia. 2002 Feb;43(2):165-9.</citation>
    <PMID>11903463</PMID>
  </reference>
  <reference>
    <citation>Volicer L, Smith S, Volicer BJ. Effect of seizures on progression of dementia of the Alzheimer type. Dementia. 1995 Sep-Oct;6(5):258-63.</citation>
    <PMID>8528372</PMID>
  </reference>
  <reference>
    <citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903. doi: 10.1073/pnas.1121081109. Epub 2012 Aug 6.</citation>
    <PMID>22869752</PMID>
  </reference>
  <reference>
    <citation>van Golde EG, Gutter T, de Weerd AW. Sleep disturbances in people with epilepsy; prevalence, impact and treatment. Sleep Med Rev. 2011 Dec;15(6):357-68. doi: 10.1016/j.smrv.2011.01.002. Epub 2011 Mar 24. Review.</citation>
    <PMID>21439869</PMID>
  </reference>
  <reference>
    <citation>Manni R, Terzaghi M. Comorbidity between epilepsy and sleep disorders. Epilepsy Res. 2010 Aug;90(3):171-7. doi: 10.1016/j.eplepsyres.2010.05.006. Epub 2010 May 31. Review.</citation>
    <PMID>20570109</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof Dr W Van Paesschen</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Alzheimer dementia</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Sleep Wake Disorders</keyword>
  <keyword>EEG</keyword>
  <keyword>Polysomnography</keyword>
  <keyword>Foramen ovale electrodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

